Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-01-23, Stock:JNJ, The news for the past five days is as follows:
2018-01-16: NEWS1: Stocks Down, Energy Play Holds Firm; This Bitcoin ETF Finds 50-Day Support.NEWS2: Notable Tuesday Option Activity: AVXS, SSYS, JNJ.NEWS3: How Important Is Keytruda To Merck?.NEWS4: Health Care Sector Update for 01/16/2018: JNJ, PFE, ABT, MRK, AMGN, BNTC, EIGR, AVXS.NEWS5: See what the IHS Markit Score report has to say about Johnson & Johnson..NEWS6: Is Johnson & Johnson a Buy?.NEWS7: Is Johnson & Johnson a Buy?.
2018-01-17: NEWS1: U.S. court invalidates patent on J&J cancer drug Zytiga.NEWS2: &quot;Fast Money&quot; final trades: JNJ, INTC and more.NEWS3: Johnson & Johnson Issues Statement on ZYTIGA® Inter Partes Reviews.NEWS4: 7 More Dividend Stocks Benefiting From the Tax Cut.NEWS5: No More Tears: Johnson & Johnson Is Still in an Uptrend and Keeping Me Humble.NEWS6: Ortho-Clinical Diagnostics SA -- Moody's affirms Ortho-Clinical's ratings, outlook revised to stable.NEWS7: SPLG, JPM, JNJ, ORCL: ETF Inflow Alert.NEWS8: 7 More Dividend Stocks Benefiting From the Tax Cut.NEWS9: Kyprolis Could Boost Amgen’s Revenue Growth in 2018.NEWS10: 3 Dividend Stocks That Pay Out Over $8 Billion a Year.NEWS11: Zoetis Inc. (ZTS) Ex-Dividend Date Scheduled for January 18, 2018.NEWS12: Johnson & Johnson Aims to Start 2018 Healthy.NEWS13: 3 Dividend Stocks That Pay Out Over $8 Billion a Year.NEWS14: Johnson & Johnson Aims to Start 2018 Healthy.NEWS15: Amgen’s Xgeva Could Witness Revenue Growth in 2018.NEWS16: Exclusive: J&J attracts Chinese interest for diabetes business in potential $3-4 billion deal - sources.
2018-01-18: NEWS1: Can These 4 Large-Cap Drug Stocks Deliver an Encore in '18?.NEWS2: Merck & Co.’s Business Segments and Performance in 3Q17.NEWS3: Can These 4 Large-Cap Drug Stocks Deliver an Encore in &apos;18?.NEWS4: Amgen Gets FDA Nod to Add ENDEAVOR Data on Kyprolis Label.NEWS5: Merck’s & Co.’s Valuation in January 2018.NEWS6: Market at New Highs: Mega Cap ETFs & Stocks On A Roll.NEWS7: Amgen Gets FDA Nod to Add ENDEAVOR Data on Kyprolis Label.NEWS8: J&J (JNJ) to Set Pharma Q4 Earnings in Motion: What's Up?.NEWS9: J&J (JNJ) Hits New 52-Week High: What's Driving the Stock?.NEWS10: J&J (JNJ) Hits New 52-Week High: What&apos;s Driving the Stock?.NEWS11: J&J (JNJ) to Set Pharma Q4 Earnings in Motion: What&apos;s Up?.NEWS12: How Amgen’s Biosimilars Are Positioned for 2018.NEWS13: See what the IHS Markit Score report has to say about Johnson & Johnson..NEWS14: How Amgen’s Enbrel and Nplate Are Positioned for 2018.NEWS15: U.S. court invalidates Johnson & Johnson cancer drug patent, hitting UK's BTG.
2018-01-19: NEWS1: Cramer's game plan: Watch individual stocks amid the earn....NEWS2: Jim Cramer breaks down his earning seasons game plan.NEWS3: Upcoming Consumer Earnings Reports to Watch: JNJ, F, SBUX.NEWS4: After Hours Most Active for Jan 19, 2018 :  MSFT, PFE, AAPL, HES, WP, MCHP, GE, JNJ, EBAY, JPM, CSCO, NKTR.NEWS5: Which Biotech Stocks Could Surprise To The Upside On Earnings?.NEWS6: Upcoming Consumer Earnings Reports to Watch: JNJ, F, SBUX.NEWS7: Should You Be Tempted To Sell Johnson & Johnson (NYSE:JNJ) Because Of Its PE Ratio?.NEWS8: Will J&J's (JNJ) Pharma Segment Pull Up its Q4 Earnings?.NEWS9: JNJ’s Recent Spine Business Developments: 4Q17 Expectations.NEWS10: Stocks Move Higher Despite Potential Government Shutdown - U.S. Commentary.NEWS11: Johnson & Johnson’s Pharmaceutical Segment: 4Q17 Estimates.NEWS12: The Zacks Analyst Blog Highlights: Johnson & Johnson, AbbVie, Amgen, Novo-Nordisk and Zoetis.NEWS13: Merck & Co.’s Diabetes Products in 3Q17.NEWS14: Will J&J&apos;s (JNJ) Pharma Segment Pull Up its Q4 Earnings?.NEWS15: What to Expect from JNJ’s Medical Device Segment in 4Q17?.NEWS16: Johnson & Johnson’s Revenue Estimates for 4Q17.NEWS17: Analysts’ Recommendations for Amgen in January 2018.NEWS18: The Zacks Analyst Blog Highlights: Johnson & Johnson, AbbVie, Amgen, Novo-Nordisk and Zoetis.NEWS19: JNJ Stock ahead of Its 4Q17 Results: Analyst Recommendations.NEWS20: Johnson & Johnson’s 4Q17 Earnings on January 23: What to Expect.NEWS21: Pharma Stock Roundup: Merck's Keytruda Shines in Study, Priority Review for Kymriah Label Expansion.NEWS22: 6 Drug Stocks With Robust Dividend Payouts.NEWS23: Pharma Stock Roundup: Merck&apos;s Keytruda Shines in Study, Priority Review for Kymriah Label Expansion.NEWS24: AptarGroup Names George Fotiades To Replace Retiring Chairman King Harris.
2018-01-22: NEWS1: These 3 Dow Stocks, This Hot Chipmaker, United Airlines Earnings On Tap: Investing Action Plan.NEWS2: These 3 Dow Stocks, This Hot Chipmaker, United Airlines Earnings On Tap: Investing Action Plan.NEWS3: [$$] Johnson & Johnson's Earnings Are Coming. Here's What to Watch..NEWS4: 3 Stocks Likely to Beat Earnings Estimates This Week.NEWS5: Dow Analyst Moves: JNJ.NEWS6: Healthcare ETFs to Watch As Q4 Earnings Unfold.NEWS7: 3 Stocks Likely to Beat Earnings Estimates This Week.NEWS8: Earnings Preview: Johnson & Johnson And Procter & Gamble Take The Stage Tomorrow Morning.NEWS9: Wynn Resorts, Imax, Johnson & Johnson, Ford and Starbucks as Zacks Bull and Bear of the Day.NEWS10: Analyst Ratings and Recommendations for Johnson & Johnson.NEWS11: Wynn Resorts, Imax, Johnson & Johnson, Ford and Starbucks as Zacks Bull and Bear of the Day.NEWS12: These 2 Developments Could Accelerate Johnson & Johnson's Next Acquisition.NEWS13: What JNJ’s Stock Valuation Tells Us.NEWS14: Johnson & Johnson’s Medical Devices Segment: 4Q17 Estimates.NEWS15: Merck & Co.’s Animal Health Business in 3Q17.NEWS16: See what the IHS Markit Score report has to say about Johnson & Johnson..NEWS17: Johnson & Johnson Is Trading at an All-Time High—What’s Next?.NEWS18: Johnson & Johnson’s Consumer Segment: 4Q17 Estimates.NEWS19: What Analysts Recommend for Bristol-Myers Squibb in January 2018.NEWS20: These 2 Developments Could Accelerate Johnson & Johnson&apos;s Next Acquisition.NEWS21: Sanofi to buy U.S. haemophilia group Bioverativ for $11.6 bln.

Answer: Decrease